National Centre for Pharmacoeconomics

National Centre for

NCPE Ireland

Pembrolizumab (Keytruda®) for Adjuvant melanoma

Pembrolizumab (Keytruda®) as monotherapy is indicated for the adjuvant treatment of adults with Stage III melanoma and lymph node involvement who have undergone complete resection.

NCPE Assessment Process Complete
Rapid review commissioned 19/11/2018
Rapid review completed 07/12/2018
Rapid Review outcome A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of pembrolizumab compared with the current standard of care.
Full pharmacoeconomic assessment commissioned by the HSE 19/12/2018
Pre-submission consultation with Applicant 14/01/2019
Submission received from Applicant 16/07/2019
Preliminary review sent to Applicant 13/11/2019
NCPE assessment recommenced 12/12/2019
Factual Accuracy sent to Applicant 01/04/2020
NCPE assessment recommenced 08/04/2020
NCPE assessment complete 15/05/2020
NCPE assessment outcome The NCPE recommends that pembrolizumab be considered for reimbursement if cost-effectiveness can be improved relative to existing treatments*.

Technical Summary

Plain English Summary

*This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.